CN102459341A - Il-13结合蛋白 - Google Patents

Il-13结合蛋白 Download PDF

Info

Publication number
CN102459341A
CN102459341A CN2010800337231A CN201080033723A CN102459341A CN 102459341 A CN102459341 A CN 102459341A CN 2010800337231 A CN2010800337231 A CN 2010800337231A CN 201080033723 A CN201080033723 A CN 201080033723A CN 102459341 A CN102459341 A CN 102459341A
Authority
CN
China
Prior art keywords
seq
binding protein
asthma
antigen binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800337231A
Other languages
English (en)
Chinese (zh)
Inventor
C·阿什曼
J·H·艾利斯
P·A·汉布林
A·P·路易斯
M·A·奥雷基亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN102459341A publication Critical patent/CN102459341A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2010800337231A 2009-05-28 2010-05-26 Il-13结合蛋白 Pending CN102459341A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18183309P 2009-05-28 2009-05-28
US61/181833 2009-05-28
US28893009P 2009-12-22 2009-12-22
US61/288930 2009-12-22
PCT/EP2010/057228 WO2010136481A1 (en) 2009-05-28 2010-05-26 Il-13 binding protein

Publications (1)

Publication Number Publication Date
CN102459341A true CN102459341A (zh) 2012-05-16

Family

ID=42335086

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800337231A Pending CN102459341A (zh) 2009-05-28 2010-05-26 Il-13结合蛋白

Country Status (21)

Country Link
US (2) US8680245B2 (cg-RX-API-DMAC7.html)
EP (1) EP2435481A1 (cg-RX-API-DMAC7.html)
JP (1) JP5919188B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120034679A (cg-RX-API-DMAC7.html)
CN (1) CN102459341A (cg-RX-API-DMAC7.html)
AR (1) AR078047A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010251955A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1016061A2 (cg-RX-API-DMAC7.html)
CA (1) CA2763443A1 (cg-RX-API-DMAC7.html)
CO (1) CO6400150A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110664A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000347A (cg-RX-API-DMAC7.html)
EA (1) EA201190275A1 (cg-RX-API-DMAC7.html)
IL (1) IL216261A0 (cg-RX-API-DMAC7.html)
MA (1) MA33381B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011012622A (cg-RX-API-DMAC7.html)
PE (1) PE20120401A1 (cg-RX-API-DMAC7.html)
SG (1) SG176203A1 (cg-RX-API-DMAC7.html)
TW (1) TW201107345A (cg-RX-API-DMAC7.html)
UY (1) UY32664A (cg-RX-API-DMAC7.html)
WO (1) WO2010136481A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849137A (zh) * 2015-10-02 2018-03-27 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
CN113156138A (zh) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
WO2024099310A1 (zh) * 2022-11-08 2024-05-16 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CN102459341A (zh) 2009-05-28 2012-05-16 葛兰素集团有限公司 Il-13结合蛋白
BR112012012887A2 (pt) 2009-12-02 2017-05-02 Imaginab Inc minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
HK1220919A1 (zh) * 2013-04-05 2017-05-19 F. Hoffmann-La Roche Ag 抗il-4抗体和双特异性抗体及其用途
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
HUE067896T2 (hu) 2016-04-27 2024-11-28 Abbvie Mfg Management Unlimited Company Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101039960A (zh) * 2004-07-01 2007-09-19 葛兰素集团有限公司 抗il－13的嵌合人源化单克隆抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
EP1499354A4 (en) 2002-05-01 2007-07-25 Regeneron Pharma METHOD OF USE OF CYTOKINE ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION AND AIDS
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
CA2636854A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
EA023031B1 (ru) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Антиген-связывающая конструкция и ее применение
NZ588853A (en) 2008-03-31 2013-07-26 Genentech Inc Compositions and methods for treating and diagnosing asthma
CN102459341A (zh) 2009-05-28 2012-05-16 葛兰素集团有限公司 Il-13结合蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101039960A (zh) * 2004-07-01 2007-09-19 葛兰素集团有限公司 抗il－13的嵌合人源化单克隆抗体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113156138A (zh) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
CN107849137A (zh) * 2015-10-02 2018-03-27 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
CN107849137B (zh) * 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
WO2024099310A1 (zh) * 2022-11-08 2024-05-16 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用

Also Published As

Publication number Publication date
BRPI1016061A2 (pt) 2016-09-13
JP2012528110A (ja) 2012-11-12
DOP2011000347A (es) 2012-01-15
KR20120034679A (ko) 2012-04-12
SG176203A1 (en) 2011-12-29
JP5919188B2 (ja) 2016-05-18
EP2435481A1 (en) 2012-04-04
WO2010136481A1 (en) 2010-12-02
CO6400150A2 (es) 2012-03-15
AU2010251955A1 (en) 2011-12-22
CA2763443A1 (en) 2010-12-02
US8680245B2 (en) 2014-03-25
MA33381B1 (fr) 2012-06-01
MX2011012622A (es) 2011-12-14
CR20110664A (es) 2012-02-27
US20100303821A1 (en) 2010-12-02
TW201107345A (en) 2011-03-01
UY32664A (es) 2010-12-31
EA201190275A1 (ru) 2012-11-30
IL216261A0 (en) 2012-01-31
PE20120401A1 (es) 2012-05-04
AR078047A1 (es) 2011-10-12
US20120082682A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
CN102459341A (zh) Il-13结合蛋白
AU2008328726B2 (en) Antigen-binding constructs
CN103946237B (zh) 白蛋白结合抗体及其结合片段
AU2008306850A1 (en) IL-23 antibodies
JP2022516881A (ja) 抗ｃｔｌａ４抗体およびその使用方法
JP2012518398A (ja) 抗原結合性構築物
JP5901517B2 (ja) 抗原結合性タンパク質
EP4019547A1 (en) Multispecific antibodies having specificity for il-4r and il-31
CN114262379B (zh) 一种pd-1/vegf四价双特异性抗体、其制备方法和用途
CN114502595A (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
CN107949570A (zh) 多特异性结合蛋白
CN119855830A (zh) Ang-2/vegf抗体及其用途
JP2012527878A (ja) 抗原結合タンパク質
TW202530256A (zh) 多特異性抗原結合多肽之組合物及使用方法
CN114929741A (zh) 针对lif的抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516